0.86
price down icon1.95%   -0.0034
 
loading
Precedente Chiudi:
$0.8566
Aprire:
$0.8566
Volume 24 ore:
557
Relative Volume:
0.00
Capitalizzazione di mercato:
$57.42M
Reddito:
$9.53M
Utile/perdita netta:
$-44.61M
Rapporto P/E:
-0.9451
EPS:
-0.91
Flusso di cassa netto:
$-38.32M
1 W Prestazione:
+12.41%
1M Prestazione:
-16.83%
6M Prestazione:
-45.09%
1 anno Prestazione:
-39.68%
Intervallo 1D:
Value
$0.8566
$0.8566
Intervallo di 1 settimana:
Value
$0.7411
$0.8599
Portata 52W:
Value
$0.45
$2.26

Cue Biopharma Inc Stock (CUE) Company Profile

Name
Nome
Cue Biopharma Inc
Name
Telefono
617-949-2680
Name
Indirizzo
40 GUEST STREET, BOSTON, MA
Name
Dipendente
41
Name
Cinguettio
@cuebiopharma
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
CUE's Discussions on Twitter

Confronta CUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CUE
Cue Biopharma Inc
0.8566 57.42M 9.53M -44.61M -38.32M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.00 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
590.34 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.34 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.12 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
248.25 24.89B 3.81B -644.79M -669.77M -6.24

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-03-13 Iniziato Jefferies Buy
2023-06-26 Ripresa Oppenheimer Outperform
2022-11-21 Iniziato Piper Sandler Overweight
2022-01-13 Iniziato H.C. Wainwright Buy
2022-01-03 Iniziato Craig Hallum Buy
2020-11-24 Iniziato Berenberg Buy
2020-04-09 Iniziato Stifel Buy
2020-01-28 Iniziato BTIG Research Buy
2020-01-22 Iniziato JMP Securities Mkt Outperform
Mostra tutto

Cue Biopharma Inc Borsa (CUE) Ultime notizie

pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 17, 2025

Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals

Apr 17, 2025
pulisher
Apr 16, 2025

Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech

Apr 15, 2025
pulisher
Apr 15, 2025

Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq

Apr 15, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Form 424B5 Cue Biopharma, Inc. - StreetInsider

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Proposed Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma to Host Business Update Call and Webcast - Enidnews.com

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma to Reveal Latest Progress in Cancer and Autoimmune Therapeutics - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

‘Buy These Two Chip Stocks Ahead of a Recession,’ Says Citi - The Globe and Mail

Apr 11, 2025
pulisher
Apr 11, 2025

S&P 500 jumps 1.8% as Wall Street closes a chaotic and historic week - The Globe and Mail

Apr 11, 2025
pulisher
Apr 11, 2025

Can Spotify’s (SPOT) Ad Business Hit the Right Notes in 2025? - The Globe and Mail

Apr 11, 2025
pulisher
Apr 10, 2025

Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail

Apr 10, 2025
pulisher
Apr 10, 2025

EXL Schedules First Quarter 2025 Financial Results Conference Call - The Globe and Mail

Apr 10, 2025
pulisher
Apr 10, 2025

Will Tariffs Destroy This Clothing Giant? - The Globe and Mail

Apr 10, 2025

Cue Biopharma Inc Azioni (CUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.39
price down icon 0.63%
$68.60
price down icon 0.25%
$32.01
price down icon 0.09%
$34.64
price down icon 7.28%
$114.80
price down icon 4.57%
biotechnology ONC
$248.25
price down icon 2.59%
Capitalizzazione:     |  Volume (24 ore):